PTGX

Protagonist Therapeutics (PTGX)

About Protagonist Therapeutics (PTGX)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Details

Daily high

$45.06

Daily low

$44.16

Price at open

$44.63

52 Week High

$48.00

52 Week Low

$13.72

Market cap

2.6B

Dividend yield

0.00%

Volume

313,585

Avg. volume

755,430

P/E ratio

16.89

Protagonist Therapeutics News